Eli Lilly and Company (NYSE:LLY) Shares Sold by Analyst IMS Investment Management Services Ltd.

Analyst IMS Investment Management Services Ltd. trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 34.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,758 shares of the company's stock after selling 916 shares during the quarter. Analyst IMS Investment Management Services Ltd.'s holdings in Eli Lilly and Company were worth $1,357,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Left Brain Wealth Management LLC grew its position in Eli Lilly and Company by 303.7% in the fourth quarter. Left Brain Wealth Management LLC now owns 4,816 shares of the company's stock worth $3,718,000 after acquiring an additional 3,623 shares in the last quarter. Northwest Wealth Management LLC grew its position in Eli Lilly and Company by 10.6% in the fourth quarter. Northwest Wealth Management LLC now owns 1,184 shares of the company's stock worth $914,000 after acquiring an additional 113 shares in the last quarter. Wellington Shields Capital Management LLC grew its position in Eli Lilly and Company by 641.9% in the fourth quarter. Wellington Shields Capital Management LLC now owns 43,960 shares of the company's stock worth $33,937,000 after acquiring an additional 38,035 shares in the last quarter. King Wealth Management Group grew its position in Eli Lilly and Company by 2.5% in the fourth quarter. King Wealth Management Group now owns 26,120 shares of the company's stock worth $20,165,000 after acquiring an additional 640 shares in the last quarter. Finally, May Barnhard Investments LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth about $309,000. 82.53% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

LLY has been the subject of several recent research reports. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a research report on Thursday, January 16th. Citigroup dropped their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Finally, StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,009.72.

Eli Lilly and Company Stock Up 1.5 %

NYSE:LLY traded up $12.00 during trading hours on Monday, reaching $825.48. The company's stock had a trading volume of 2,545,442 shares, compared to its average volume of 3,115,528. The company has a market capitalization of $782.70 billion, a P/E ratio of 70.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a 50 day moving average price of $830.81 and a two-hundred day moving average price of $842.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its stock is undervalued.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.